A Phase 1, Multi-center, Open-label, Single-dose Study to Assess the Pharmacokinetics of Mezigdomide (BMS-986348, CC-92480) in Adult Participants With Normal Renal Function, Severe Renal Impairment, and End-stage Renal Disease

简要总结

主要结局

次要结局

• Number of participants with adverse events (AEs)(Up to 54 days)
• Number of participants with serious adverse events (SAEs)(Up to 54 days)
• Number of participants with physical examination findings(Up to 24 days)
• Number of participants with vital sign abnormalities(Up to 24 days)
• Number of participants with 12-lead electrocardiogram (ECG) findings(Up to 24 days)
• Maximum observed concentration (Cmax)(Up to 24 days)
• Time of maximum observed concentration (Tmax)(Up to 24 days)
• Area under the plasma concentration-time curve (AUC)(Up to 24 days)